Trials / Completed
CompletedNCT00625846
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- National Cancer Institute (NCI) · NIH
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor.
Detailed description
PRIMARY OBJECTIVE: I. To establish the safety and efficacy of GW786034 (pazopanib hydrochloride) as a therapeutic in patients afflicted with differentiated, medullary and anaplastic thyroid cancers. CORRELATIVE OBJECTIVES: I. Assessment of the impact of therapy with GW786034 on serum/plasma vascular endothelial growth factor (VEGF) levels. II. To explore the potential relationship between changes in thyroglobulin levels and tumor response in patients with advanced differentiated thyroid cancer known to be thyroglobulin antibody negative. OUTLINE: Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for up to 3 years after registration.
Conditions
- Recurrent Thyroid Gland Carcinoma
- Stage III Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage III Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7
- Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7
- Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7
- Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7
- Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7
- Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
- Thyroid Gland Anaplastic Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Laboratory Biomarker Analysis | Correlative studies |
| DRUG | Pazopanib Hydrochloride | Given PO |
Timeline
- Start date
- 2008-02-22
- Primary completion
- 2018-12-21
- Completion
- 2019-08-13
- First posted
- 2008-02-28
- Last updated
- 2020-02-26
- Results posted
- 2020-02-26
Locations
22 sites across 5 countries: United States, Australia, China, Singapore, Taiwan
Source: ClinicalTrials.gov record NCT00625846. Inclusion in this directory is not an endorsement.